• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[Psychotropic drug-related weight gain-Are incretins/twincretins an option?].

作者信息

Paulzen Michael

机构信息

Alexianer Aachen GmbH, Alexianer Zentrum für seelische Gesundheit Aachen | Gangelt, Alexianergraben 33, 52062, Aachen, Deutschland.

出版信息

Nervenarzt. 2025 Jan;96(1):93-96. doi: 10.1007/s00115-024-01788-1. Epub 2025 Jan 8.

DOI:10.1007/s00115-024-01788-1
PMID:39774952
Abstract
摘要

相似文献

1
[Psychotropic drug-related weight gain-Are incretins/twincretins an option?].[精神药物相关体重增加——肠促胰岛素/双效肠促胰岛素是一种选择吗？]
Nervenarzt. 2025 Jan;96(1):93-96. doi: 10.1007/s00115-024-01788-1. Epub 2025 Jan 8.
2
The emerging role of incretins and twincretins.肠促胰岛素和双促胰岛素的新作用
Nat Rev Endocrinol. 2022 Feb;18(2):73-74. doi: 10.1038/s41574-021-00607-w.
3
Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.基于双重肠促胰岛素受体激活的糖尿病和肥胖治疗：“双激素”。
Diabetes Obes Metab. 2016 Sep;18(9):847-54. doi: 10.1111/dom.12685. Epub 2016 Jun 7.
4
Psychotropic drug-induced genetic-epigenetic modulation of CRTC1 gene is associated with early weight gain in a prospective study of psychiatric patients.精神药物诱导的 CRTC1 基因遗传-表观遗传调控与精神科患者前瞻性研究中的早期体重增加有关。
Clin Epigenetics. 2019 Dec 26;11(1):198. doi: 10.1186/s13148-019-0792-0.
5
Weight gain associated with taking psychotropic medication: an integrative review.服用精神类药物导致的体重增加：综合述评。
Int J Ment Health Nurs. 2011 Jun;20(3):202-22. doi: 10.1111/j.1447-0349.2010.00721.x. Epub 2011 Feb 18.
6
Weight Gain and Mental Health in the Canadian Prison Population.加拿大监狱人口的体重增加与心理健康。
J Correct Health Care. 2021 Mar;27(1):51-57. doi: 10.1089/jchc.19.04.0039.
7
Psychotropic drugs, eating behaviour and weight gain.精神药物、饮食行为与体重增加。
Curr Opin Psychiatry. 2024 Sep 1;37(5):331-336. doi: 10.1097/YCO.0000000000000953. Epub 2024 Jun 10.
8
Induction of obesity by psychotropic drugs.精神药物诱发肥胖
Ann N Y Acad Sci. 1987;499:203-15. doi: 10.1111/j.1749-6632.1987.tb36212.x.
9
The effect of a novel dietary intervention on weight loss in psychotropic drug-induced obesity.一种新型饮食干预对精神药物所致肥胖患者体重减轻的影响。
Psychopharmacol Bull. 2002 Summer;36(3):55-9.
10
[Update twincretins: first clinical experience and important facts].[双促胰岛素：首次临床经验及重要事实更新]
MMW Fortschr Med. 2024 Dec;166(21-22):67-69. doi: 10.1007/s15006-024-4428-8.

本文引用的文献

1
Disproportionality Analysis From World Health Organization Data on Semaglutide, Liraglutide, and Suicidality.从世界卫生组织关于司美格鲁肽、利拉鲁肽和自杀的数据中进行不均衡分析。
JAMA Netw Open. 2024 Aug 1;7(8):e2423385. doi: 10.1001/jamanetworkopen.2024.23385.
2
Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.胰高血糖素和 GLP-1 受体双重激动剂索马鲁肽治疗肥胖症的随机、双盲、安慰剂对照、剂量探索 2 期临床试验。
Lancet Diabetes Endocrinol. 2024 Mar;12(3):162-173. doi: 10.1016/S2213-8587(23)00356-X. Epub 2024 Feb 5.
3
Psychotropic Drug-Related Weight Gain and Its Treatment.
精神药物相关体重增加及其治疗。
Am J Psychiatry. 2024 Jan 1;181(1):26-38. doi: 10.1176/appi.ajp.20230922.
4
Semaglutide for the treatment of antipsychotic-associated weight gain in patients not responding to metformin - a case series.司美格鲁肽治疗二甲双胍治疗无效的抗精神病药物所致体重增加患者——病例系列
Ther Adv Psychopharmacol. 2023 Apr 19;13:20451253231165169. doi: 10.1177/20451253231165169. eCollection 2023.
5
Reduction in Multiple Cardiometabolic Risk Factors With Combined Olanzapine/Samidorphan Compared With Olanzapine: Post Hoc Analyses From a 24-Week Phase 3 Study.与奥氮平相比，奥氮平/萨米多弗联合治疗可降低多种心血管代谢风险因素：一项 24 周 3 期研究的事后分析。
Schizophr Bull. 2023 Mar 15;49(2):454-463. doi: 10.1093/schbul/sbac144.
6
Tirzepatide Once Weekly for the Treatment of Obesity.司美格鲁肽每周一次治疗肥胖症。
N Engl J Med. 2022 Jul 21;387(3):205-216. doi: 10.1056/NEJMoa2206038. Epub 2022 Jun 4.
7
Metformin in the management of antipsychotic-induced weight gain in adults with psychosis: development of the first evidence-based guideline using GRADE methodology.二甲双胍治疗精神分裂症成人抗精神病药引起的体重增加：使用 GRADE 方法制定的首个循证指南。
Evid Based Ment Health. 2022 Feb;25(1):15-22. doi: 10.1136/ebmental-2021-300291. Epub 2021 Sep 29.
8
Antipsychotics Use Is Associated With Greater Adherence to Cardiometabolic Medications in Patients With Schizophrenia: Results From a Nationwide, Within-subject Design Study.抗精神病药物的使用与精神分裂症患者对心脏代谢药物的更高依从性相关：一项全国范围内的个体内设计研究的结果。
Schizophr Bull. 2022 Jan 21;48(1):166-175. doi: 10.1093/schbul/sbab087.
9
Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: a systematic review and meta-analysis.精神障碍患者精神药物治疗不依从及其相关因素的系统评价和荟萃分析。
Syst Rev. 2020 Jan 16;9(1):17. doi: 10.1186/s13643-020-1274-3.
10
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.利拉鲁肽治疗对接受氯氮平或奥氮平治疗的精神分裂症谱系障碍患者前驱糖尿病及超重或肥胖的影响：一项随机临床试验
JAMA Psychiatry. 2017 Jul 1;74(7):719-728. doi: 10.1001/jamapsychiatry.2017.1220.